Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
van Wijk FH, Aapro MS, Bolis G, Chevallier B, van der Burg ME, Poveda A, de Oliveira CF, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TA, Ploch E, Beex LV, ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JE, Teodorovic I, Coens C, Vergote I, Vermorken JB; European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. van Wijk FH, et al. Among authors: van der burg me. Ann Oncol. 2003 Mar;14(3):441-8. doi: 10.1093/annonc/mdg112. Ann Oncol. 2003. PMID: 12598351 Free article. Clinical Trial.
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.
Aapro MS, van Wijk FH, van der Burg ME, ten Bokkel Huinink W, Vergote I, Guastalla JP, Rosso R, Kobierska A, Beex LV, Namer M, Splinter TE, Vermorken JB. Aapro MS, et al. Among authors: van wijk fh, van der burg me. Eur J Cancer. 2003 May;39(8):1141-3. doi: 10.1016/s0959-8049(03)00198-9. Eur J Cancer. 2003. PMID: 12736114 Clinical Trial.
Molecular portrait of the progestagenic and estrogenic actions of tibolone: behavior of cellular networks in response to tibolone.
Hanifi-Moghaddam P, Gielen SC, Kloosterboer HJ, De Gooyer ME, Sijbers AM, van Gool AJ, Smid M, Moorhouse M, van Wijk FH, Burger CW, Blok LJ. Hanifi-Moghaddam P, et al. Among authors: van wijk fh. J Clin Endocrinol Metab. 2005 Feb;90(2):973-83. doi: 10.1210/jc.2004-1423. Epub 2004 Nov 30. J Clin Endocrinol Metab. 2005. PMID: 15572424
Recurrent endometrial cancer: a retrospective study.
van Wijk FH, Huikeshoven FJ, Abdulkadir L, Ewing PC, Burger CW. van Wijk FH, et al. Eur J Obstet Gynecol Reprod Biol. 2007 Jan;130(1):114-20. doi: 10.1016/j.ejogrb.2005.12.014. Epub 2006 Feb 3. Eur J Obstet Gynecol Reprod Biol. 2007. PMID: 16460871
Histological and immunohistochemical evaluation of postmenopausal endometrium after 3 weeks of treatment with tibolone, estrogen only, or estrogen plus progestagen.
Klaassens AH, van Wijk FH, Hanifi-Moghaddam P, Sijmons B, Ewing PC, Ten Kate-Booij MJ, Kooi GS, Kloosterboer HJ, Blok LJ, Burger CW. Klaassens AH, et al. Among authors: van wijk fh. Fertil Steril. 2006 Aug;86(2):352-61. doi: 10.1016/j.fertnstert.2005.12.077. Epub 2006 Jul 7. Fertil Steril. 2006. PMID: 16828477 Free article. Clinical Trial.
Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen + progestagen signaling.
Hanifi-Moghaddam P, Boers-Sijmons B, Klaassens AH, van Wijk FH, den Bakker MA, Ott MC, Shipley GL, Verheul HA, Kloosterboer HJ, Burger CW, Blok LJ. Hanifi-Moghaddam P, et al. Among authors: van wijk fh. J Mol Med (Berl). 2007 May;85(5):471-80. doi: 10.1007/s00109-006-0146-1. Epub 2007 Jan 17. J Mol Med (Berl). 2007. PMID: 17226044 Free PMC article. Clinical Trial.
113 results